人体胎盘脂多糖辅助治疗初治菌阳肺结核患者疗效及细胞因子观察

Clinical effects and cytokine of Human Placenta Lipopolysaccharide assisted method in treatment of new smear-positive tuberculosis patients

目的观察人体胎盘脂多糖辅助治疗初治菌阳肺结核疗效及细胞因子的变化。方法将60例初治菌阳肺结核患者随机分为治疗组和对照组,两组各为30例,均用相同的抗结核治疗,治疗组加用人体胎盘脂多糖。结果治疗二个月后,治疗组痰菌阴转率为96.7%,X线病灶吸收好转率93.3%;与对照组80%,70%,相比较差异有显著性(P<0.05)。T淋巴细胞亚群和血清细胞因子IL-4治疗前后及IFN-γ两组比较均有差异显著(P<0.01),未见明显副作用。结论人体胎盘脂多糖与化疗药物联合应用可提高初治菌阳肺结核疗效,使用安全。并能提高患者细胞免疫,使初治菌阳阴转率高,病灶吸收快。

Objective To observe the clinical effects and sytokine of Human Placenta Lipopolysaceharide assisted method in treatment of new smear-positive tuberculosis patients. Methods A total of 60 new diagnosed cases with smear-positive tuberculosis patients were randomly divided into two groups： the treatment group（n=30） who received Human Placenta Lipopolysaccharide combined chemotherapy and the control grcup（n= 30） who received combined chemotherapy only. Results The sputum bacteria negtive rate, the pulmonary tuberculosis lesion ahsorption rate after 2-month treatment for the treatment group were 96.7%, 93.3%; respectively, for the controls the rates were 80%,70%, respectively. The rates between the two groups were significant difference （P〈0.05）. respectively the oneself comparison T lymphocytes and the serum level of IL-4 were significant difference; IFN-γwere significantly higher than the control group（P〈0.01）. However, the side effects between the twogrcups were similar. Conclusions Use of Human Placenta Lipopolysaccharide combined with chemotherapy may increase clinical effects in treatment new smear-positive tuberculosis patients, and it is safe, increase the cell immune function, of patients.